CD274 and gastric cancer: In the Asian population, Nivolulab was approved for the treatment of the unresectable, advanced, or recurrent gastric cancer that has progressed after using conventional chemotherapy, based on the results from the phase III ATTRACTION-2 trial, regardless of PD-L1 status.